With respect to hepatic complications (hepatitis), the female gender and a history of hepatitis were found to increase its odds upon treatment with anti-PD1 or anti-PD-L1 [OR = 2.71; 95% CI 1.07–6.85, OR = 11.14; 95% CI 3.46–35.88, respectively], whereas previous exposure to cancer therapy was the only factor that increased the odds of having respiratory complications (pneumonia) among the treated patients [OR = 3.08; 95% CI 1.12–8.85]. Here, PDCD1 is linked to hepatitis A virus infection.